+44 (0)1223 330484
enquiries@hughes.cam.ac.uk

By-Fellow

Dr Perla Pucci is a research associate and co-PI in molecular oncology at the Department of Pathology of the University of Cambridge and a By-Fellow at Hughes Hall. Her work is focussed on the study of the molecular mechanisms that drive resistance to cancer treatments, particularly focussing on the epigenome and transcriptome using highthroughput approaches  such as genome-wide CRISPR/CAS9 and drug screens and aims to discover novel personalized combination treatments to improve patients` quality of life and survival.

Perla has shown the role of long noncoding RNAs and micro RNAs in the regulation of cancer resistance to therapy, in incurable subtypes of prostate cancer and high-risk neuroblastoma. Her
work has been published in several high impact journals, including in Nature Communications, the EMBO journal, Trends in Pharmacological Sciences and Molecular Cancer. Her work has been selected for presentations at international events such the European Society of Molecular Oncology Congress and the American Association for Cancer Research Meeting.

Perla is a member of the Editorial Board of Epigenomics and Frontiers in Oncology. Currently, she is leading a project awarded by the Little Princess Trust in partnership with the Children’s Cancer and Leukaemia Group (CCLG), to investigate the epigenetic changes in the histone code in high-risk neuroblastoma and to develop clinical applications to monitor and treat this aggressive cancer. During her work of the last years, she has also developed model systems that have led to many collaborations, one of which was recently facilitated by the successful award of a grant from the Medical Research Council (MRC), assessing a novel therapeutic approach for the treatment of neuroblastoma which has contributed to the generation of data for a patent that was recently granted and will hopefully contribute to translating this evidence into a Phase 1 Clinical trial.